Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced that it intends to offer and sell $125 million of its common stock, subject ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE